Korean J Urol.  1992 Dec;33(6):974-978.

Prostate specific antigen as a tumor marker for adenocarcinoma of the prostate

• Kim SG
• Hong JM
• Paik SK
• Kim TK

Abstract

Serum prostate specific antigen (PSA) and prostate acid phosphatase (PAP) were measured in 106 patients including 9 patients with prostate cancer, 63 patients with BPH. and 34 normal control group free of prostate disorders. The mean PSA value was 61.14+/-43.87 ng/ml for prostate cancer, 6.07+/-5.57 ng/ml for BPH and 1.42+/-0.98 ng/ml for normal control group, and the mean PAP value was 9.81+/-10.16 ng/ml for prostate cancer, 1.58+/-2.36ng/ml for BPH and 1.00+/-0.17 ng/ml for normal control group. The positive rates of PSA were 78% for prostate cancer, 22% for BPH and 0% for normal control group, and those of PAP were 67% for prostate cancer, 6% for BPH and 0% for normal control group. The sensitivity and specificity for PSA were 78%, respectively. We conclude that PSA may be a useful tool for detection and therapeutic monitoring of the prostatic cancer.

Keyword

prostate specific antigen; prostate cancer

MeSH Terms

Acid Phosphatase
Adenocarcinoma*
Humans
Prostate*
Prostate-Specific Antigen*
Prostatic Neoplasms
Sensitivity and Specificity
Acid Phosphatase
Prostate-Specific Antigen